Microbiological Filtration Application Guide
Microbiological Filtration Conditions & Solutions
PP · PES · Hydrophobic PTFE · Hydrophilic PTFE · PVDF · Nylon
This guide compares PP, PES, hydrophobic PTFE, hydrophilic PTFE, PVDF and Nylon across different retention ratings for representative liquid, gas and equipment-vent applications. It also defines the validation boundaries for sterilizing filtration, mycoplasma risk reduction, compatibility and integrity testing.
01 — 06
Microbiological Filtration Selection and Validation Route
01Define the fluid and control objective→
02Measure solids and bioburden→
03Clarify and protect with prefiltration→
04Select membrane and pore rating→
05Validate integrity and process performance→
06Maintain sterility or release quality
Key Conclusions
This guide identifies candidate membrane materials and retention ratings. It does not replace model-specific bacterial or mycoplasma challenge studies, integrity-test correlation, compatibility testing with the actual fluid, adsorption and recovery studies, or sterilization validation.
| Control objective | Suggested rating | Preferred media | Procurement and validation boundary |
|---|---|---|---|
| Visible particles or cell debris | 5–50 µm | PP depth or pleated media | Protects downstream equipment; not a microbiological-control grade |
| Fine particles and yeast or mould load reduction | 0.6–3 µm | PP, PES, PVDF, Nylon | Clarification or bioburden reduction; no sterility claim |
| Finer bioburden reduction | 0.45/0.65 µm | PES, PVDF, Nylon, hydrophilic PTFE | Often used as a prefilter or for load reduction; generally not a final sterilizing grade |
| Liquid sterilizing filtration | 0.20/0.22 µm | PES, hydrophilic PVDF, hydrophilic PTFE; Nylon only for qualified models | The complete assembly requires challenge and validation data; equal pore ratings do not imply equal performance grades |
| Mycoplasma risk reduction | 0.10 µm | Mainly dedicated PES/PVDF models | Verify a specific challenge claim, such as A. laidlawii |
| Sterile gas or equipment venting | 0.20 µm | Hydrophobic PTFE; selected hydrophobic PVDF | Prevent condensation and inadvertent wetting, and verify post-use integrity |
Conditions, Risks and Recommendations
| Application | Primary risks | Recommended combination | Format | Confirm before selection |
|---|---|---|---|---|
| Culture medium or feed solution | Nutrient-rich fluid, undissolved powder, and bacterial or mycoplasma risk | 0.45–1.2 µm prefilter; 0.20/0.22 µm PES or hydrophilic PVDF; use a dedicated 0.10 µm claim where mycoplasma risk is high | Pleated cartridges for large batches; presterilized capsules for small batches | Post-filtration sterile hold, culture performance and the mycoplasma claim |
| Buffer or process water | Salt precipitation, undissolved particles and bioburden during storage | 1–5 µm PP protection; 0.45 or 0.20 µm PES/PVDF; 0.20 µm hydrophobic PTFE for tank venting | Pleated cartridges in fixed lines; capsules in single-use systems | Differential pressure, hold time and bioburden before and after filtration |
| WFI/PW point of use | Stagnant branches, filter dead legs and recontamination | Prioritize hygienic-system control; local 0.20/0.22 µm PES/PVDF/hydrophilic PTFE may be considered | Low-flow capsule or cartridge in a hygienic housing | Service life, flushing and integrity; not an endotoxin-removal step |
| High-concentration protein or mAb | High viscosity, aggregates, adsorption and initial-volume loss | Compare 0.20/0.22 µm PES with hydrophilic PVDF; use a 0.45/0.2 µm double layer or separate prefilter when needed | Low-hold-up capsules preferred for development or clinical batches | Minimum temperature, maximum concentration, longest contact time, recovery and potency |
| Viral vector or oncolytic virus | Particle size close to the pore rating, HCP/aggregate contamination and titre loss | Start with small-area PES/PVDF comparisons and 0.45–0.8 µm prefilter screening; never infer recovery from the membrane name | Low-hold-up capsule | Titre, HCP, TMP/differential pressure and membrane area; validate product by product |
| mRNA-LNP or nanoparticles | The 50–200 nm particle distribution overlaps a 0.2 µm pore distribution | Screen 0.20/0.22 µm PES/PVDF; assess a 0.4–0.8 µm prefilter or 0.8/0.2 µm structure | Capsules preferred for development and clinical batches | Particle size/PDI, encapsulation efficiency, recovery and capacity; do not scale from water flow alone |
| Whole-cell or aluminium-adjuvanted vaccine | The target component is larger than the pore or readily blocks the membrane | Do not use final 0.2 µm filtration as a universal solution; sterilize or aseptically control individual components before blending where appropriate | Select by component | Product filterability, potency and particle-size distribution |
| Alcohol-containing or mixed-solvent drug solution | Swelling of the membrane, support or seal, and API adsorption | Prefer hydrophilic PTFE; compare Nylon; assess PES/PVDF for aqueous systems | Pleated cartridge for batch processing; solvent-compatible capsule for small batches | Complete-assembly soak, extractables, and API recovery from initial and steady-state fractions |
| Corrosive aqueous or oxidizing fluid | Strong acids, alkalis or oxidants can affect surface treatment and seals | Screen hydrophilic PTFE; do not infer complete-cartridge compatibility from the PTFE membrane alone | Fixed cartridge or dedicated capsule | Concentration, temperature, contact time and compatibility after sterilization |
| Sterile air, N₂ or CO₂ | Aerosols, oil/water mist and condensate wetting | Remove oil and water upstream; use 0.20 µm hydrophobic PTFE at the terminal point | Pleated cartridge for high flow; capsule for small vessels | Gas challenge/integrity, maximum gas demand, wettest condition and post-use test |
| Fermenter or reactor exhaust | Saturated humidity, foam, condensate blockage and backpressure | Use 0.20 µm hydrophobic PTFE with vertical drainage; add a prefilter, condenser or heat tracing for high-risk service | Pleated cartridge for large vessels; capsule for small reactors | Wet flow, backpressure, foam events, SIP direction and post-use integrity |
| Lyophilizer, storage tank or sterilizer vent | Vacuum break, cooling air intake and condensation | 0.20 µm sterilizing-grade hydrophobic PTFE; selected validated hydrophobic PVDF | SIP-capable cartridge preferred for fixed equipment | In-situ integrity, maximum service duration and cumulative sterilization cycles |
| QC/HPLC sample | Trace particles and membrane adsorption can bias the analysis | Compare PES/PVDF/hydrophilic PTFE for protein samples; use Nylon/PTFE for compatible solvent samples | Small-area capsule or disc; keep analytical-grade use separate from GMP production | Discard volume, recovery from initial and steady-state fractions, and filtration area |
Recommendations by Membrane and Rating
PP | Preferred for clarification, particle protection and bioburden reduction
| Rating | Suggested application | Engineering or procurement focus | Claim boundary |
|---|---|---|---|
| 5–50 µm | Cell debris, visible particles and resin fines; protection of downstream membranes | Prefer a true depth structure; pleated PP area alone cannot replace depth capacity | Not for bacterial control |
| 1–5 µm | Preclarification of fermentation/harvest fluids, buffers and chromatography pools | Select by absolute or nominal rating, Beta ratio and differential-pressure curve | Clarification or load reduction |
| 0.6–1 µm | Fine prefiltration of colloidal or high-load liquids | Confirm whether the construction is a microporous membrane, nonwoven medium or composite layer; capacities differ | Load reduction, not sterile filtration |
| 0.2–0.22 µm | Consider only where the specific model has bacterial challenge data | Most PP products are better suited to prefiltration or bioburden reduction; pore rating is not a sterilizing claim | Limited to the model-specific claim |
PES | Primary membrane for aqueous biopharmaceutical liquids
| Rating | Suggested application | Engineering or procurement focus | Claim boundary |
|---|---|---|---|
| 0.8/0.2 or 0.45/0.2 µm | Double-layer or graded structures for media, buffers and protein solutions | Used to increase capacity; challenge testing and integrity correlation still apply to the final membrane layer | Prefilter plus terminal filter |
| 0.45 µm | Load reduction or clarification of difficult-to-filter liquids | Not a routine final sterilizing grade | Load reduction |
| 0.20/0.22 µm | Media, buffers, process water, mAb and selected virus/LNP processes | Choose a complete assembly supported by an ASTM F838-equivalent challenge and process-validation data | Candidate for liquid sterilizing filtration |
| 0.10 µm | Mycoplasma risk reduction | Require the specific challenge organism, challenge conditions, and an LRV or no-penetration claim; pore rating alone is insufficient | Dedicated mycoplasma-control candidate |
Hydrophobic PTFE | Sterile gases, equipment vents and compatible solvents
| Rating | Suggested application | Engineering or procurement focus | Claim boundary |
|---|---|---|---|
| 1–5 µm | Upstream particle or oil-mist protection for compressed gas | Does not replace the terminal sterile-gas membrane | Gas prefilter |
| 0.45 µm | Low-risk gas-particle control or terminal-membrane protection | Do not treat as a sterile-gas grade without a bacterial challenge claim | Load reduction or protection |
| 0.20 µm | Air, N₂, CO₂, and tank, lyophilizer or reactor venting | Verify the gas bacterial challenge, integrity method, condensate/wet-flow capability and sterilization cycles | Sterile-gas candidate |
| 0.20/0.22 µm liquid | Organic solvent compatible with PTFE | Aqueous fluids usually require prewetting; prewetting changes the process and adds validation complexity | Solvent-liquid candidate |
Hydrophilic PTFE | Corrosive aqueous and solvent-containing drug solutions
| Rating | Suggested application | Engineering or procurement focus | Claim boundary |
|---|---|---|---|
| 0.45–5 µm | Particle prefiltration of corrosive or solvent-containing liquids | Verify surface treatment, support, housing and seals; do not apply hydrophobic-PTFE data | Prefiltration |
| 0.20/0.22 µm | Alcohol-containing aqueous solutions, selected corrosive drug fluids, and small-molecule/API solutions | Use as a sterilizing grade only where the specific cartridge has liquid bacterial challenge and integrity data | Candidate for liquid sterilizing filtration |
| 0.10 µm (selected models) | More stringent microbiological-risk control | Obtain a dedicated challenge claim; do not extrapolate from material or pore rating | Dedicated models only |
PVDF | Low-binding biological liquids and selected gas applications
| Rating | Suggested application | Engineering or procurement focus | Claim boundary |
|---|---|---|---|
| 0.45/0.22 µm | Graded prefilter plus terminal filter for protein/antibody, vaccine or virus processes | Hydrophilic treatment and membrane morphology vary substantially; compare recovery and capacity with the actual product | Prefilter plus terminal filter |
| 0.45/0.65 µm | Clarification, bioburden reduction and downstream-membrane protection | Generally not a final sterilizing grade | Load reduction |
| 0.20/0.22 µm | Proteins, antibodies, media, buffers and selected ophthalmic/parenteral solutions | Choose a bacterial-challenged hydrophilic PVDF cartridge; validate adsorption, potency and integrity | Candidate for liquid sterilizing filtration |
| 0.10 µm | Mycoplasma risk reduction | Procure against specific challenge data such as A. laidlawii | Dedicated mycoplasma-control candidate |
| 0.20 µm hydrophobic PVDF | Selected vent-gas applications | Only for models with sterile-gas challenge, wet-condition and integrity data | Gas candidate |
Nylon | Compatible solvents and small molecules; use cautiously with proteins
| Rating | Suggested application | Engineering or procurement focus | Claim boundary |
|---|---|---|---|
| 1–5 µm | Particle prefiltration of solvents or small-molecule drug solutions | Verify compatibility with strong acids, strong alkalis, oxidants and halogenated solvents | Prefiltration |
| 0.45/0.65 µm | Clarification of HPLC/QC samples and small-molecule drug solutions | Record discard volume and recovery from initial and steady-state fractions | Clarification or load reduction |
| 0.20/0.22 µm | Compatible solvents and small-molecule/API solutions | Use for sterilizing filtration only when the specific model has bacterial challenge, complete-assembly compatibility and recovery data | Candidate for liquid sterilizing filtration |
Microorganisms and Pore-Rating Decisions
| Target | Applicable rating or strategy | Validation required | Invalid inference |
|---|---|---|---|
| Common vegetative bacteria | Validated complete 0.20/0.22 µm filter | Conduct a bacterial challenge with the worst-case process fluid or a suitable surrogate; ASTM F838 commonly uses B. diminuta, with a typical challenge level of ≥10⁷ CFU/cm² | Do not promise retention from a size list for a particular bacterium |
| Mycoplasma | Dedicated 0.10 µm model | Verify challenge data such as A. laidlawii, culture conditions, penetration results and integrity correlation | Some mycoplasma can penetrate 0.2/0.22 µm; 0.1 µm is not an automatic barrier either |
| Yeast | 0.45–1 µm for load reduction; validate 0.2/0.22 µm for terminal sterility | Feed concentration, particles/flocs, differential pressure and flux | A particle larger than the pore rating does not by itself establish regulatory sterilizing grade |
| Mould or spores | 0.45–1 µm often for load reduction; use a validated terminal filter at the critical sterile boundary | Spore morphology, agglomeration, fluid viscosity and prefilter capacity | Load-reduction results do not replace final sterility assurance |
| Bacteriophage or virus | Conventional 0.2 µm microfiltration is not a general virus-removal step | Use dedicated virus filtration, inactivation or orthogonal controls; emphasize recovery when the product contains virus | Do not claim that 0.2 µm universally removes viruses |
| Endotoxin | Conventional microfiltration generally does not remove dissolved endotoxin | Control through the water system, raw materials and process hygiene; use dedicated removal technology where required | Endotoxin may remain after 0.2 µm filtration |
Pleated Cartridge or Capsule Filter
| Format | Suitable applications | Advantages | Key risks |
|---|---|---|---|
| Pleated cartridge and housing | Fixed production lines, large batches, multiple-batch operation, high area demand or SIP | Large scalable area, lower cost per unit area and in-situ integrity testing | Housing cleaning/sterilization and installation seals; the cartridge-housing combination must be validated |
| Presterilized capsule | R&D, pilot, clinical or small batches, single-use flow paths and closed transfer | Low hold-up, rapid assembly and reduced cleaning validation | Not every product supports SIP; verify SAL, package integrity, maximum differential pressure and connections |
| Series or redundant arrangement | High-contamination risk, critical terminal steps or processes requiring online verification | Can share capacity or provide additional risk control | Series installation is not automatically redundant; define the integrity-test scope and deviation strategy |
RFQ and Technical-Confirmation Checklist
| Field | Required information |
|---|---|
| 1. Filtration duty | Clarification, bioburden reduction, liquid sterilizing filtration, mycoplasma control, sterile gas or equipment protection; do not state only “pharmaceutical grade” |
| 2. Fluid information | Full liquid/gas name, component concentrations, pH, temperature, viscosity, surfactants, organic solvents, oxidants and planned contact time |
| 3. Microbiological boundary | Target organism or risk source, prefiltration bioburden, whether an ASTM F838-equivalent challenge is required, and whether a dedicated mycoplasma claim is needed |
| 4. Process scale | Batch volume, target time, actual flow, initial/final differential pressure, maximum allowable differential pressure, hold time and maximum flux |
| 5. Pretreatment | Centrifugation, depth filtration or PP prefiltration, existing pore rating, double-layer status, feed turbidity/particle size/aggregates and filtration curve |
| 6. Product quality | Recovery, potency, protein/virus/LNP concentration, particle size/PDI, aggregates, initial/steady-state samples and filter hold-up |
| 7. Complete assembly | Membrane, prefilter layer, support/drainage layer, core, cage, end caps, housing, welds, connectors and O-ring/seal materials |
| 8. Sterilization | SIP, autoclave, irradiation or EO; maximum temperature/time/dose, direction, count, cumulative cycles, SAL and shelf life |
| 9. Integrity test | Water intrusion, diffusive flow, bubble point or pressure hold; wetting fluid, temperature, test pressure, limit, area conversion and post-use pathway |
| 10. Documentation | Specification, validation guide, challenge claim, CoC/CoA, factory integrity, sterilization certificate, E&L, change notification and traceability period |